Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551421 · ClinicalTrials.gov registry record · Phase 1
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00551421: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00551421 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00551421, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pertuzumab together with cetuximab may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of pertuzumab when given together with cetuximab and to see how well they work in treating patients with previously treated locally advanced or metastatic colorectal cancer
Interventions
- OTHER immunohistochemistry staining method
- BIOLOGICAL cetuximab
- BIOLOGICAL pertuzumab
- DRUG irinotecan hydrochloride
- OTHER fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551421
The ClinicalTrials.gov registry entry for NCT00551421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which immunohistochemistry staining method is the first listed.
NCT00551421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00551421 about?
NCT00551421 is a clinical study titled "Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer". Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving pertuzumab together with cetuximab may kill more t...
What is the current status of trial NCT00551421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2007-10. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00551421?
The interventions under investigation include: immunohistochemistry staining method (OTHER), cetuximab (BIOLOGICAL), pertuzumab (BIOLOGICAL), irinotecan hydrochloride (DRUG), fluorescence in situ hybridization (OTHER).
Who is sponsoring clinical trial NCT00551421?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.